The mitochondrial disorder is a general term for a group of disorders that can affect many different organs. There is no specific treatment for these disorders, although the symptoms they cause can be treated with medication, surgery, or diet.
One important goal in treating patients with mitochondrial disorders is to avoid medications that are toxic to mitochondrial function.
A medication can affect many different functions in the mitochondria. The mitochondrial respiratory chain (MRС) consists of five enzyme complexes: IV and uses cytochrome c and coenzyme Q10, which act as electron carriers. Pharmacotherapy-induced MRС dysfunction can result from direct inhibition of one or more of the enzyme complexes or from disconnection of oxidative phosphorylation.
Most of the evidence for effects on the mitochondrial disease organism comes from in vitro or preclinical studies. In addition, because of the wide variety of manifestations of mitochondrial disease in different patients, different results can be reported for the same drug.
Drugs to avoid in patients with mitochondrial disease:
Medicine |
Proposed mechanism |
Adverse effects related to mitochondrial toxicity |
Amiodarone |
Inhibits MRC I and III and beta oxidation |
Pulmonary toxicity, microvesicular steatosis and liver failure |
Antibiotics: |
Reduces mt protein synthesis |
Deafness, renal failure, myopathy |
Anti-cancer medicines: doxorubicin, cisplatin |
mtDNA mutation |
Cardiomyopathy |
Antipsychotics: haloperidol, risperidone, clozapine |
Inhibits MRC I, increases reactive oxygen species, inhibits oxidative phosphorylation |
Extrapyramidal symptoms, metabolic syndrome |
Aspirin |
Inhibits oxidative phosphorylation and beta oxidation |
Causes a Reye-like syndrome |
Beta-blockers: metoprolol, propranolol |
Inhibits MRC I |
Case report of muscle wasting |
Ciprofibrate |
Inhibits MRC I, weak peroxisome proliferator activated receptor ligand |
Myopathy and rhabdomyolysis |
Corticosteroids |
Inhibit mt membrane potential, generate reactive oxygen species |
Myopathy |
Fluoxetine |
Inhibits MRC I and V, interferes with cytochrome c |
Gastrointestinal damage |
Isoflurane |
Inhibits MRC I |
Hepatotoxicity |
Isoflurane / halothane / sevoflurane |
Inhibits MRC I |
Hepatotoxicity, neurotoxicity cardiac effects |
Linezolid |
Inhibits mt protein synthesis |
Polyneuropathy and lactic acidosis |
Local anaesthetics: bupivicane, lidocaine |
Inhibtis MRC V, increases reactive oxygen species, inhibits oxidative phosphorylation |
Myopathy |
Metformin |
Inhibits MRC I |
Causes lactic acidosis |
Nicotine |
Inhibits respiratory chain |
|
Non-steroidal anti-inflammatory drugs: |
Inhibits oxidative phosphorylation and beta oxidation |
Hepatotoxicity |
Nucleoside reverse transcriptase inhibitors: |
mtDNA depletion which then affects all functions |
Encephalomyopathy, anaemia, polyneuropathy, pancreatitis and lactic acidosis |
Paracetamol (overdose) |
MRC I |
Hepatotoxicity |
Phenytoin |
Inhibits mt ATPase |
Case report of intestinal pseudo obstruction, may cause hepatotoxicity |
Pioglitazone |
Inhibits MRC I, weak, peroxisome proliferator activated receptor ligand |
Increases anaerobic glycolysis |
Propofol (particularly > 4 mg/kg/h for > 48 hours) |
Inhibition of free fatty acid entry to mt, beta oxidation |
Propofol infusion syndrome: metabolic acidosis, rhabdomyolysis, heart failure, hepatomegaly, asystole |
Sertraline |
Inhibits MRC I and V, inhibits oxidative phosphorylation |
Hepatotoxicity |
Simvastatin (other statins have weaker effects) |
Inhibits MRC I, reduces coenzyme Q10 levels, weak peroxisome proliferator activated receptor ligand |
Causes myopathy, rhabdomyolysis |
Sodium valproate |
Inhibits oxidative phosphorylation, beta-oxidation |
Liver failure, hyperammoninaemia, hypoglycaemia, steatosis and encephalopathy |
Tricyclic antidepressants: |
Inhibits MRC |
Extrapyramidal symptoms, memory impairmentмт - мітохондрії |
*Table in alphabetical order, which is not the same as order of importance of the medicines.
mt = mitochondria